These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36264948)

  • 1. Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort.
    Vallejo-Yagüe E; Pfund JN; Burkard T; Clair C; Micheroli R; Möller B; Finckh A; Burden AM
    PLoS One; 2022; 17(10):e0275026. PubMed ID: 36264948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort.
    Vallejo-Yagüe E; Burkard T; Micheroli R; Burden AM
    BMJ Open; 2022 Sep; 12(9):e061474. PubMed ID: 36115672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.
    Burkard T; Vallejo-Yagüe E; Hügle T; Finckh A; Burden AM
    BMJ Open; 2022 Mar; 12(3):e056352. PubMed ID: 35292498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
    Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
    PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study.
    Kaban N; Harman H
    Int J Rheum Dis; 2023 Apr; 26(4):689-698. PubMed ID: 36807751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors.
    Arnold S; Jaeger VK; Scherer A; Ciurea A; Walker UA; Kyburz D
    Rheumatology (Oxford); 2021 Dec; 61(1):131-138. PubMed ID: 33848332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study.
    Tada M; Matsumoto Y; Koike T; Mamoto K; Nakamura T; Anno S; Iida T; Goto H; Hidaka N
    Int J Rheum Dis; 2024 Oct; 27(10):e15371. PubMed ID: 39381837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients.
    Burkard T; Williams RD; Vallejo-Yagüe E; Hügle T; Finckh A; Kyburz D; Burden AM
    Rheumatol Adv Pract; 2021; 5(3):rkab087. PubMed ID: 34888435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.
    Qi W; Robert A; Singbo N; Ratelle L; Fortin PR; Bessette L; Brown JP; Michou L
    Adv Rheumatol; 2024 Aug; 64(1):55. PubMed ID: 39107865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
    Källmark H; Einarsson JT; Nilsson JÅ; Olofsson T; Saxne T; Geborek P; C Kapetanovic M
    Arthritis Rheumatol; 2021 Jul; 73(7):1135-1144. PubMed ID: 33682353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
    Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
    Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
    McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
    Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study.
    Lee SW; Kim SY; Chang SH
    BMC Musculoskelet Disord; 2019 Sep; 20(1):420. PubMed ID: 31506089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort.
    Geng Y; Han J; Deng X; Zhang Z
    Clin Rheumatol; 2014 Aug; 33(8):1061-6. PubMed ID: 24777468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of blue-collar vs. white-collar occupations on disease burden in psoriatic arthritis patients: A Swiss clinical quality management in rheumatic diseases cohort study.
    Colla N; Maul JT; Vallejo-Yagüe E; Burden AM; Möller B; Nissen MJ; Yawalkar N; Papagiannoulis E; Distler O; Ciurea A; Micheroli R
    Clin Rheumatol; 2024 Oct; 43(10):3147-3155. PubMed ID: 39110326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.
    Zhao SS; Kearsley-Fleet L; Bosworth A; Watson K; ; Hyrich KL
    Rheumatology (Oxford); 2022 Nov; 61(12):4678-4686. PubMed ID: 35357421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
    Li X; Cesta A; Movahedi M; Bombardier C
    Arthritis Res Ther; 2022 Nov; 24(1):255. PubMed ID: 36401335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis.
    Shin S; Park EH; Kang EH; Lee YJ; Song YW; Ha YJ
    Joint Bone Spine; 2021 May; 88(3):105124. PubMed ID: 33346105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.